The effect of famotidine on renal function in patients with renal insufficiency
- PMID: 2889461
- PMCID: PMC1386262
- DOI: 10.1111/j.1365-2125.1987.tb03185.x
The effect of famotidine on renal function in patients with renal insufficiency
Abstract
The effect of famotidine, a new histamine H2-receptor antagonist, on renal tubular creatinine secretion was evaluated in twelve patients with reduced renal function (creatinine clearance 10-60 ml min-1). Creatinine and inulin clearances were determined at baseline and for 4 h after a 10 mg intravenous dose of famotidine. Famotidine renal clearance exceeded inulin clearance by an average of 152%, indicating that renal tubular secretion of famotidine occurred. No significant changes in the clearances of creatinine or inulin, or the fractional clearance of creatinine were observed after famotidine administration. These data suggest that famotidine, unlike cimetidine, does not inhibit renal tubular secretion of creatinine. Thus, famotidine does not affect creatinine-dependent measurements of renal function and is unlikely to alter the renal elimination of basic drugs.
Similar articles
-
Effects of famotidine, a new histamine H2-receptor antagonist, on renal function.Nihon Jinzo Gakkai Shi. 1989 Jun;31(6):687-91. Nihon Jinzo Gakkai Shi. 1989. PMID: 2571741
-
[The effect of H2 receptor blockers on renal function. An attempt to accurately measure glomerular filtration].Ann Acad Med Stetin. 2004;50(1):97-105. Ann Acad Med Stetin. 2004. PMID: 16871748 Clinical Trial. Polish.
-
Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.Eur J Clin Pharmacol. 1988;34(1):41-6. doi: 10.1007/BF01061415. Eur J Clin Pharmacol. 1988. PMID: 2896129
-
Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.Clin Pharmacokinet. 1991 Mar;20(3):218-36. doi: 10.2165/00003088-199120030-00004. Clin Pharmacokinet. 1991. PMID: 1673880 Review.
-
Clinical pharmacokinetics of famotidine.Clin Pharmacokinet. 1991 Sep;21(3):178-94. doi: 10.2165/00003088-199121030-00003. Clin Pharmacokinet. 1991. PMID: 1764869 Review.
Cited by
-
Renal effects of peptic ulcer therapy.Drug Saf. 1992 Jul-Aug;7(4):282-91. doi: 10.2165/00002018-199207040-00004. Drug Saf. 1992. PMID: 1524700 Review.
-
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002. Clin Pharmacokinet. 1990. PMID: 2199130 Review.
-
Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population.CPT Pharmacometrics Syst Pharmacol. 2020 Dec;9(12):695-706. doi: 10.1002/psp4.12566. Epub 2020 Nov 23. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 33049120 Free PMC article.
-
Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.Clin Pharmacokinet. 1988 Oct;15(4):205-15. doi: 10.2165/00003088-198815040-00001. Clin Pharmacokinet. 1988. PMID: 2903807 Review.
-
Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.Eur J Clin Pharmacol. 1989;36(5):517-20. doi: 10.1007/BF00558079. Eur J Clin Pharmacol. 1989. PMID: 2568929
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous